Polyreactive Antibodies in Immunological Assays: Origins, Detection, and Clinical Interpretation

Sadi Koksoy, PhD, HCLD (ABB) and Aristo Vojdani, PhD

Summary

Polyreactive antibodies bind to unrelated antigens and are frequently detected in antigen-antibody reaction-based assays. While they can complicate interpretation, they provide important biological and clinical insights. Polyreactivity may reflect normal immune function, transient immune activation (including infections, fungal exposure, or chemical toxins), or loss of immune tolerance associated with autoimmunity. Proper identification and reporting of polyreactivity are essential for accurate interpretation and clinical decision-making.

Cyrex Laboratories` ELISA-based approach provides an important diagnostic layer by simultaneously characterizing a serum sample as polyreactive while isolating and reporting high-affinity, clinically significant antibodies. This **dual-reporting capability** prevents the misinterpretation of "sticky" serum as a series of false positives, ensuring that clinicians receive a clear distinction between broad immune activation and targeted, clinically relevant pathology.

1. Overview

Polyreactive antibodies are defined as immunoglobulins capable of binding to structurally unrelated antigens, including proteins, peptides, lipids, and nucleic acids.

In immunological assays, they may result in:

- Broad, nonspecific binding
- Elevated background signal
- Apparent multi-antigen positivity

Importantly, polyreactivity is a **recognized immunological phenomenon**, not simply an assay artifact. As a leader in the field of immunological laboratory methods, Cyrex recognizes the importance of this phenomenon and comprehensively addresses it.

2. Immunological Sources of Polyreactivity

2.1 Natural (Physiologic) Polyreactivity

- Present in healthy individuals
- Often IgM, sometimes IgG and IgA is also well documented, particularly in mucosal immunity
- Plays roles in:
    - Early pathogen defense
    - Clearance of apoptotic debris
    - Microbiome homeostasis

2.2 Polyreactivity Triggered by Immune Activation: Infections, Fungi, and Toxins after binding to Human Tissue Proteins

Polyreactivity commonly increases following immune activation.

Triggers include:

- Viral: EBV, CMV, HHV-6, influenza, SARS-CoV-2
- Bacterial: *Mycoplasma pneumoniae*, *Streptococcus* spp.
- Parasitic: *Plasmodium* spp.
- Fungal exposure/infection: *Candida*, *Aspergillus*, *Penicillium, Stachybotrys*
- Toxins: endotoxins, inflammatory microbial products, and chemicals that cause the formation of neo-antigens

Mechanistically, this reflects polyclonal B cell activation and expansion of low-affinity clones that produce low-affinity antibodies.

Key point: This state is typically transient.

2.3 Polyreactivity Triggered by Loss of Immune Tolerance (Autoimmunity)

- Persistent, higher affinity polyreactivity
- Often class-switched (IgG and/or IgA)
- Includes self-reactivity

3. Laboratory Identification and Reporting

Detection of polyreactivity is clinically important and should be explicitly reported.

When identified:

- Cyrex Labs will release the initial polyreactive results as a preliminary polyreactive result. Cyrex will then repeat the test using its proprietary Poly-R™ methodology at no cost to the provider to reveal **higher-affinity, antigen-specific antibodies** that have the most clinical relevance. Then these higher-affinity final results will be sent to the providers with the following header: **"Polyreactive Serum (or Oral Fluid)."**

4. Clinical Implications

Polyreactivity may indicate:

- Recent immune activation (infection, fungi, toxins)
- Mucosal immune activity (often IgA-driven)
- Possible **loss of tolerance and emerging autoimmunity**

Thus, it is a **clinically meaningful signal**, not merely background noise and therefore needs resolution.

5. Follow-Up and Longitudinal Assessment

- **Repeat testing recommended after 3 to 6 months**

Interpretation:

- **Resolution** → transient immune activation
- **Persistence** → possible immune dysregulation

Concern for autoimmunity increases when combined with:

- **↑ T helper 1 (Th1)**
- **↑ T helper 17 (Th17)**
- **↓ Regulatory T cells (Treg)**

(as identified via Cyrex's The Lymphocyte Map™ (LMAP) or similar immune profiling).

6. Visual Clinical Decision Flowchart



7. Conclusion

Polyreactive antibodies are a normal yet clinically informative feature of the immune system. Their detection may reflect:

1. Physiologic immune surveillance
2. Transient activation (infection, fungi, toxins)
3. Persistent immune dysregulation and autoimmunity

Key principle:
Polyreactivity should be **reported, further analyzed (via dilution), and followed longitudinally**, rather than dismissed or overinterpreted.

Cyrex demonstrates its leadership in the field of immunological laboratory methods in its recognition of the importance of this phenomenon and comprehensively addressing it.

---

8. References

References for further educational reading:

1. Pashov AD. *Antibody Polyreactivity: A Challenger of Immune Paradigms.* (2025)

2. Lecerf M et al. *Polyreactivity of antibodies from different B-cell subpopulations.* Frontiers in Immunology (2023)

3. Zhou ZH et al. *Properties and function of polyreactive antibodies.* Journal of Autoimmunity (2007)

4. Bunker JJ et al. *Natural polyreactive IgA antibodies coat intestinal microbiota.* Science (2017)

5. Carnero LAR et al. *Identification of polyreactive antibodies by ELISA and SPR.* Journal of Immunological Methods (2025)

6. Harvey EP et al. *In silico method to assess antibody polyreactivity.* Nature Communications (2022)

7. Boughter CT et al. *Biochemical patterns of antibody polyreactivity.* eLife (2020)

8. Cunningham O et al. *Polyreactivity in therapeutic antibody development.* mAbs / Taylor & Francis (2021)